Journal Club E47: SURPASS-CVOT: Tirzepatide Is at Least as Good as Dulaglutide for Heart Disease in Type 2 Diabetes

from AZense Journal Club · host Azense Medical Education

Is tirzepatide non-inferior to dulaglutide for MACE prevention in T2DM with established CVD?

Episode metadata supplied by the publisher feed · Published Feb 23, 2026

Embed this episode

Attribution link and audio player

Ready to play

Journal Club E47: SURPASS-CVOT: Tirzepatide Is at Least as Good as Dulaglutide for Heart Disease in Type 2 Diabetes

0:00 7:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 7 minutes long.

This episode was published on February 23, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!